Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/117349
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Costs of invasive meningococcal disease: a global systematic review
Author: Wang, B.
Santoreneos, R.
Afzali, H.
Giles, L.
Marshall, H.
Citation: PharmacoEconomics, 2018; 36(10):1201-1222
Publisher: Springer
Issue Date: 2018
ISSN: 1170-7690
1179-2027
Statement of
Responsibility: 
Bing Wang, Renee Santoreneos, Hossein Afzali, Lynne Giles, Helen Marshall
Abstract: Background: Invasive meningococcal disease remains a public health concern because of its rapid onset and significant risk of death and long-term disability. New meningococcal serogroup B and combination serogroup ACWY vaccines are being considered for publicly funded immunization programs in many countries. Contemporary costing data associated with invasive meningococcal disease are required to inform cost-effectiveness analyses. Objective: The objective of this study was to estimate costs and resource utilization associated with acute infection and the long-term care of invasive meningococcal disease. Data Sources and Methods: PubMed, EMBASE, The Cochrane Library, health economic databases, and electronically available conference abstracts were searched. Studies reporting any costs associated with acute infection and long-term sequelae of invasive meningococcal disease in English were included. All costs were converted into purchasing power parity-adjusted estimates [international dollars (I$)] using the Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre cost converter. Results: Fourteen studies met our eligibility criteria and were included. The mean costs of acute admission ranged from I$1629 to I$50,796, with an incremental cost of I$16,378. The mean length of hospital stay was reported to be 6-18 days in multiple studies. The average costs reported for readmissions ranged from I$7905 to I$15,908. Key variables such as the presence of sequelae were associated with higher hospitalization costs and longer inpatient stay. No studies estimated direct non-healthcare costs and productivity loss. Ten studies reported only unadjusted mean values without using appropriate statistical methods for adjustment. Conclusions: Invasive meningococcal disease can result in substantial costs to healthcare systems. However, costing data on long-term follow-up and indirect costs used to populate health economic models are lacking.
Keywords: Humans; Meningococcal Infections; Hospitalization; Length of Stay; Models, Economic; Cost-Benefit Analysis; Health Care Costs; Hospital Costs
Rights: © Springer International Publishing AG, part of Springer Nature 2018
RMID: 0030090744
DOI: 10.1007/s40273-018-0679-5
Grant ID: http://purl.org/au-research/grants/nhmrc/1084951
Appears in Collections:Public Health publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.